SCHEMBL15053576

SCHEMBL15053576

[2H]C([2H])(c1c[nH]c2ncccc12)n1ccc2c(NC(=O)Nc3ccccc3C)cccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 3/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
MTNR1A P48039 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
STAT3 P40763 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MET P08581 1/20 0.39
CCNB2 O95067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3699011 0.91 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDMAPTRAB9A
Hydrochloric Acid SCHEMBL3706766 0.90 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL15052682 0.90 MAPT (0.43) ALDH1A1KDM4EHPGDMAPTMTNR1A
SCHEMBL15053861 0.89 BRAF (0.47) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL15053077 0.89 HTT (0.44) KDM4ERAB9ANPC1MTNR1AKMT2A
SCHEMBL15053884 0.89 MAPT (0.42) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL15053932 0.89 ITGB2 (0.42) ALDH1A1KDM4EHPGDRAB9ANPC1
SCHEMBL15053977 0.89 MAPT (0.44) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL15052955 0.88 KMT2A (0.43) ALDH1A1KDM4EMAPTMTNR1AKMT2A
SCHEMBL15053095 0.87 RAB9A (0.39) ALDH1A1KDM4EHPGDMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US claimed
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165475-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK2, CDK1, CDK3 ALDH1A1 4512/4885KDM4E 900/4885HPGD 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.